<DOC>
	<DOCNO>NCT01031459</DOCNO>
	<brief_summary>The purpose study investigate clinical status patient participate original pivotal Betaseron study 20 year randomize treatment initiationStudy end-points include : 1 . Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality 2 . EDSS ( Expanded Disability Status Scale ) 3 . Cognition 4 . Resource use 5 . SPMS ( Secondary Progressive Multiple Sclerosis ) status 6 . Employment history</brief_summary>
	<brief_title>Telephone Interview Patients That Participated Pivotal Betaferon MS Trial .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Previously enrol Betaseron pivotal study protocol TB0135686 US TB0135886 Canada ( total , N=372 ) Patient , caregiver , legal guardian must provide write informed consent Patient must confirm her/his ability agreement participate study begin phone call</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>